Suppr超能文献

提高溶出度、开发制剂并评估卢立康唑非离子囊泡凝胶剂的抗真菌活性。

Solubility enhancement, formulation development and antifungal activity of luliconazole niosomal gel-based system.

机构信息

Akal College of Pharmacy and Technical Education, Sangrur, Punjab, India.

Department of Pharmacy, Vishwabharathi College of Pharmaceutical Sciences, Guntur, Andhra Pradesh, India.

出版信息

J Biomater Sci Polym Ed. 2021 Jun;32(8):1009-1023. doi: 10.1080/09205063.2021.1892471. Epub 2021 Mar 11.

Abstract

Luliconazole is a potential prescription candidate drug for the treatment of topical fungal infections. However, it has water solubility and skin permeability limitations. To overcome these limitations, a niosomal gel of luliconazole was formulated using Span 60, cholesterol, and chloroform to improve its bioavailability and to reduce its toxicity. Niosomes were analyzed by transmission electron microscopy (TEM) and Fourier transform infrared spectroscopy (FTIR) for morphological and spectral studies respectively. The formulations had ideal nanometric vesicle sizes, encapsulation efficiency (88.891% ± 0.0364%), Zeta potential (-40.1 mV), and storage instability was not observed. The sustained-release profile of niosomal gel was observed for up to 24 h. The highest R value was 0.913; the Higuchi model was considered the best fit model for the niosomal formulations. Cytotoxicity studies confirmed the biocompatibility of the niosomal gel of luliconazole. Based on the results, it can be concluded that niosomal luliconazole may enhance the activity of luliconazole against ().

摘要

卢立康唑是一种有潜力的治疗局部真菌感染的处方候选药物。然而,它的水溶性和皮肤渗透性有限。为了克服这些限制,用司盘 60、胆固醇和氯仿制备了卢立康唑的非离子囊泡凝胶,以提高其生物利用度并降低其毒性。通过透射电子显微镜(TEM)和傅里叶变换红外光谱(FTIR)分别对囊泡进行形态学和光谱学研究。这些制剂具有理想的纳米囊泡大小、包封效率(88.891%±0.0364%)、Zeta 电位(-40.1 mV),且未观察到储存不稳定性。非离子囊泡凝胶的缓释曲线可观察长达 24 h。最高 R 值为 0.913;Higuchi 模型被认为是非离子囊泡制剂的最佳拟合模型。细胞毒性研究证实了卢立康唑非离子囊泡凝胶的生物相容性。基于这些结果,可以得出结论,非离子囊泡卢立康唑可能增强卢立康唑对 ()的活性。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验